Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 314

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 314
---
 financings for a period of
60 days following the closing of the offering, subject to an exception; and (ii) a covenant to not enter into any equity financings for
45 days from closing of the offering, subject to certain exceptions.

Insider Participation

A director of the Company has agreed to purchase an aggregate of 510,200
Pre-Funded Warrants and accompanying Common Warrants to purchase 510,200 of Common Stock, for a total purchase price of approximately
$1,000,000, at the public offering price and on the same terms as the other purchasers in this offering.

Other Relationships

From time to time, the placement
agent may provide in the future various advisory, investment and commercial banking and other services to us in the ordinary course of
business, for which they have received and may continue to receive customary fees and commissions.

Regulation M Compliance

The placement agent may
be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any
profit realized on the sale of our securities offered hereby by it while acting as principal might be deemed to be underwriting discounts
or commissions under the Securities Act. The placement agent will be required to comply with the requirements of the Securities
Act and the Exchange Act, including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations
may limit the timing of purchases and sales of our securities by the placement agent. Under these rules and regulations, the placement
agent may not (i) engage in any stabilization activity in connection with our securities; and (ii) bid for or purchase any of our securities
or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed
their participation in the distribution.

Determination of Offering Price

The actual offering price
of the securities we are offering were negotiated between us, the placement agent and the investors in the offering based on the trading
of our Common Stock prior to the offering, among other things. Other factors considered in determining the public offering price of the
securities we are offering, as well as the exercise price of the Offered Common Warrants and Pre-Funded Warrants that we are offering,
include our history and prospects, the stage of development of our business, our business plans for the future and the extent to which
they have been implemented, an assessment of our management, the